Resistance to CDK4/6 Inhibitors in Estrogen Receptor-Positive Breast Cancer

Estrogen receptor-positive (ER+) breast cancer is the most common form of breast cancer. Antiestrogens were the first therapy aimed at treating this subtype, but resistance to these warranted the development of a new treatment option. CDK4/6 inhibitors address this problem by halting cell cycle prog...

Descripción completa

Detalles Bibliográficos
Autores principales: Scheidemann, Erin R., Shajahan-Haq, Ayesha N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8625090/
https://www.ncbi.nlm.nih.gov/pubmed/34830174
http://dx.doi.org/10.3390/ijms222212292

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8625090/
https://www.ncbi.nlm.nih.gov/pubmed/34830174
http://dx.doi.org/10.3390/ijms222212292

Ejemplares similares